Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2024 07:05 ET | Source: Celcuity Inc.

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with a...
November 14, 2024 16:01 ET | Source: Celcuity Inc.

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash...
November 12, 2024 16:05 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference ...
November 12, 2024 07:05 ET | Source: Celcuity Inc.

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
November 07, 2024 07:05 ET | Source: Celcuity Inc.

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
October 29, 2024 06:00 ET | Source: Orion Oyj

Orion Group Interim Report January–September 2024

ORION CORPORATION INTERIM REPORT 1–9/2024 29 OCTOBER 2024 at 12:00 EET Orion Group Interim Report January–September 2024 Net sales totalled EUR 1,108.0 (January–September 2023: 868.5) million...
October 24, 2024 04:27 ET | Source: Research and Markets

Understand the United States Prostate Cancer Patient Experience in 2023: Demographics, Impact on Quality of Life, Information-seeking Behaviors, HCP Engagement, Treatment Awareness and Experiences

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Prostate Cancer in the United States: Understanding the Prostate Cancer Patient Experience" report has been added to ResearchAndMarkets.com's...
October 14, 2024 04:00 ET | Source: Orion Oyj

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s...
September 26, 2024 04:15 ET | Source: Research and Markets

Prostate Cancer in the United States: Key Insights into Treatment Awareness & Satisfaction - Make Informed, Strategic Decisions, Identify Opportunities, and Understand Potential Challenges

Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Prostate Cancer in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ...
September 26, 2024 04:00 ET | Source: Orion Oyj

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

ORION CORPORATION INVESTOR NEWS 26 SEPTEMBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become...